| Summary of disaggregates revenues by major revenue streams |
The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. In alignment with Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under Teva’s United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change. conjunction with a recent shift in executive management responsibilities and in alignment with Teva’s Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Teva’s North America segment as of January 1, 2024. From that date Canada is reported as part of the Company’s International Markets segment and Teva’s North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective January 1, 2024. Amounts for the year ended December 31, 2023 have been recast to conform to the reporting structure.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of goods |
|
|
7,081 |
|
|
|
4,959 |
|
|
|
2,039 |
|
|
|
526 |
|
|
|
14,605 |
|
| Licensing arrangements* |
|
|
607 |
|
|
|
39 |
|
|
|
28 |
|
|
|
4 |
|
|
|
678 |
|
| Distribution |
|
|
— |
|
|
|
1 |
|
|
|
54 |
|
|
|
1,496 |
|
|
|
1,551 |
|
| Other** |
|
|
2 |
|
|
|
41 |
|
|
|
41 |
|
|
|
339 |
|
|
|
423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
7,690 |
|
|
$ |
5,040 |
|
|
$ |
2,162 |
|
|
$ |
2,365 |
|
|
$ |
17,258 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Revenues from licensing arrangements in United States segment were mainly comprised of development milestone payments of $500 million received in the fourth quarter of 2025, in connection with the initiation of Phase 3 studies for duvakitug ( anti-TL1A ). See note 2. |
| ** |
“Other” revenues in Europe and International Markets segments include revenues related to sales of certain product rights. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Year ended December 31, 2024 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| Sale of goods |
|
|
6,327 |
|
|
|
4,891 |
|
|
|
2,280 |
|
|
|
553 |
|
|
|
14,050 |
|
| Licensing arrangements |
|
|
103 |
|
|
|
35 |
|
|
|
24 |
|
|
|
11 |
|
|
|
173 |
|
| Distribution |
|
|
— |
|
|
|
1 |
|
|
|
39 |
|
|
|
1,536 |
|
|
|
1,576 |
|
| Other* |
|
|
68 |
|
|
|
176 |
|
|
|
121 |
|
|
|
380 |
|
|
|
745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,498 |
|
|
$ |
5,103 |
|
|
$ |
2,463 |
|
|
$ |
2,480 |
|
|
$ |
16,544 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
“Other” revenues in United States, Europe and International Markets segments include revenues related to sales of certain product rights. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of goods |
|
|
5,554 |
|
|
|
4,631 |
|
|
|
2,229 |
|
|
|
565 |
|
|
|
12,979 |
|
| Licensing arrangements* |
|
|
597 |
|
|
|
51 |
|
|
|
28 |
|
|
|
5 |
|
|
|
681 |
|
| Distribution |
|
|
— |
|
|
|
|
§ |
|
|
38 |
|
|
|
1,577 |
|
|
|
1,615 |
|
| Other** |
|
|
2 |
|
|
|
155 |
|
|
|
57 |
|
|
|
357 |
|
|
|
570 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,154 |
|
|
$ |
4,837 |
|
|
$ |
2,351 |
|
|
$ |
2,503 |
|
|
$ |
15,846 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Revenues from licensing arrangements in United States segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2. |
| ** |
“Other” revenues in Europe segment mainly related to the sale of certain product rights. |
| § |
Represents an amount less than $0.5 million.
|
|
| Summary of Sales Reserves and Allowances |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales Reserves and Allowances |
|
|
|
Reserves
included in
Accounts
Receivable,
net |
|
|
|
|
|
Medicaid and
other
governmental
allowances |
|
|
|
|
|
|
|
|
|
|
|
Total
reserves
included in
Sales
Reserves
and
Allowances |
|
|
|
|
|
|
|
|
Balance at January 1, 2025 |
|
$ |
56 |
|
|
$ |
1,674 |
|
|
$ |
561 |
|
|
$ |
936 |
|
|
$ |
399 |
|
|
$ |
108 |
|
|
$ |
3,678 |
|
|
$ |
3,734 |
|
Provisions related to sales made in current year period |
|
|
412 |
|
|
|
5,129 |
|
|
|
1,050 |
|
|
|
8,005 |
|
|
|
289 |
|
|
|
124 |
|
|
|
14,597 |
|
|
|
15,009 |
|
Provisions related to sales made in prior periods |
|
|
— |
|
|
|
(46 |
) |
|
|
44 |
|
|
|
(29 |
) |
|
|
(15 |
) |
|
|
(12 |
) |
|
|
(58 |
) |
|
|
(58 |
) |
Credits and payments |
|
|
(405 |
) |
|
|
(4,869 |
) |
|
|
(970 |
) |
|
|
(7,995 |
) |
|
|
(233 |
) |
|
|
(131 |
) |
|
|
(14,198 |
) |
|
|
(14,603 |
) |
Translation differences |
|
|
— |
|
|
|
66 |
|
|
|
16 |
|
|
|
20 |
|
|
|
5 |
|
|
|
17 |
|
|
|
124 |
|
|
|
124 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2025 |
|
$ |
63 |
|
|
$ |
1,954 |
|
|
$ |
701 |
|
|
$ |
937 |
|
|
$ |
445 |
|
|
$ |
106 |
|
|
$ |
4,143 |
|
|
$ |
4,206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Sales Reserves and Allowances |
|
| |
|
Reserves
included in
Accounts
Receivable,
net |
|
|
|
|
|
Medicaid and
other
governmental
allowances |
|
|
|
|
|
|
|
|
|
|
|
Total
reserves
included in
Sales
Reserves
and
Allowances |
|
|
|
|
| |
|
|
|
Balance at January 1, 2024 |
|
$ |
61 |
|
|
|
1,603 |
|
|
|
540 |
|
|
|
859 |
|
|
|
436 |
|
|
|
97 |
|
|
$ |
3,535 |
|
|
$ |
3,596 |
|
Provisions related to sales made in current year period |
|
|
390 |
|
|
|
4,640 |
|
|
|
787 |
|
|
|
7,952 |
|
|
|
276 |
|
|
|
149 |
|
|
|
13,804 |
|
|
|
14,194 |
|
Provisions related to sales made in prior periods |
|
|
— |
|
|
|
5 |
|
|
|
22 |
|
|
|
(11 |
) |
|
|
(22 |
) |
|
|
(3 |
) |
|
|
(9 |
) |
|
|
(9 |
) |
Credits and payments |
|
|
(395 |
) |
|
|
(4,531 |
) |
|
|
(781 |
) |
|
|
(7,851 |
) |
|
|
(286 |
) |
|
|
(126 |
) |
|
|
(13,575 |
) |
|
|
(13,970 |
) |
Translation differences |
|
|
— |
|
|
|
(43 |
) |
|
|
(7 |
) |
|
|
(13 |
) |
|
|
(5 |
) |
|
|
(9 |
) |
|
|
(77 |
) |
|
|
(77 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2024 |
|
$ |
56 |
|
|
$ |
1,674 |
|
|
$ |
561 |
|
|
$ |
936 |
|
|
$ |
399 |
|
|
$ |
108 |
|
|
$ |
3,678 |
|
|
$ |
3,734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|